TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

March 27, 2026 updated by: Asmaa Hassan mohamed Abdel Mawjoud
  1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients.
  2. Detect relation between TNFAIP3 and disease activity.

Inclusion criteria:

  1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10).

  2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).

    b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984.

2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)

Exclusion Criteria:

  • Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ankylosing spondylitis
Diagnostic test: Detection of TNFAIP3 gene expression by real time PCR.
Detection of TNFAIP3 gene expression by real time PCR.
Experimental: psoriatic arthritis patients
Diagnostic test: Detection of TNFAIP3 gene expression by real time PCR.
Detection of TNFAIP3 gene expression by real time PCR.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors .
Time Frame: 18 months
18 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Detect relation between TNFAIP3 and ankylosing spondylitis apsoriatic arthritis activity. detection of TNFAIP3 gene expression by real time PCR will be done for every subject.
Time Frame: 20 months
20 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asmaa Hassan mohamed Abdel Mawjoud

Collaborators

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 2, 2026

Study Record Updates

Last Update Posted (Actual)

April 2, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TNFAIP3 gene expression

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ankylosing Spondylitis and Psoriatic Arthritis Patients

Clinical Trials on Detection of TNFAIP3 gene expression by real time PCR.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe